ACADIA Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 3/6
ACADIA Pharmaceuticals has been growing earnings at an average annual rate of 24.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.4% per year. ACADIA Pharmaceuticals's return on equity is 5.9%, and it has net margins of 3.4%.
Belangrijke informatie
24.5%
Groei van de winst
27.0%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 11.5% |
Inkomstengroei | 18.4% |
Rendement op eigen vermogen | 5.9% |
Nettomarge | 3.4% |
Volgende winstupdate | 06 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe ACADIA Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 891 | 31 | 434 | 0 |
31 Mar 24 | 814 | -2 | 413 | 0 |
31 Dec 23 | 726 | -61 | 407 | 0 |
30 Sep 23 | 632 | -149 | 399 | 0 |
30 Jun 23 | 551 | -111 | 380 | 0 |
31 Mar 23 | 520 | -146 | 374 | 0 |
31 Dec 22 | 517 | -216 | 369 | 0 |
30 Sep 22 | 512 | -217 | 371 | 0 |
30 Jun 22 | 512 | -205 | 374 | 0 |
31 Mar 22 | 493 | -214 | 381 | 0 |
31 Dec 21 | 484 | -168 | 396 | 0 |
30 Sep 21 | 474 | -192 | 411 | 0 |
30 Jun 21 | 463 | -262 | 411 | 0 |
31 Mar 21 | 458 | -260 | 398 | 0 |
31 Dec 20 | 442 | -282 | 389 | 0 |
30 Sep 20 | 419 | -268 | 360 | 0 |
30 Jun 20 | 393 | -225 | 351 | 0 |
31 Mar 20 | 366 | -238 | 335 | 0 |
31 Dec 19 | 339 | -235 | 326 | 0 |
30 Sep 19 | 300 | -248 | 308 | 0 |
30 Jun 19 | 264 | -268 | 296 | 0 |
31 Mar 19 | 238 | -276 | 298 | 0 |
31 Dec 18 | 224 | -245 | 266 | 0 |
30 Sep 18 | 208 | -249 | 258 | 0 |
30 Jun 18 | 185 | -252 | 259 | 0 |
31 Mar 18 | 158 | -256 | 250 | 0 |
31 Dec 17 | 125 | -289 | 255 | 0 |
30 Sep 17 | 93 | -299 | 246 | 0 |
30 Jun 17 | 63 | -306 | 235 | 0 |
31 Mar 17 | 33 | -309 | 225 | 0 |
31 Dec 16 | 17 | -271 | 186 | 0 |
30 Sep 16 | 5 | -238 | 151 | 0 |
30 Jun 16 | 0 | -206 | 121 | 0 |
31 Mar 16 | 0 | -174 | 92 | 0 |
31 Dec 15 | 0 | -164 | 79 | 0 |
30 Sep 15 | 0 | -147 | 67 | 0 |
30 Jun 15 | 0 | -133 | 54 | 0 |
31 Mar 15 | 0 | -115 | 41 | 0 |
31 Dec 14 | 0 | -92 | 33 | 0 |
30 Sep 14 | 0 | -76 | 27 | 0 |
30 Jun 14 | 0 | -62 | 22 | 0 |
31 Mar 14 | 1 | -50 | 17 | 0 |
31 Dec 13 | 1 | -38 | 13 | 0 |
Kwaliteitswinsten: 0A4W has high quality earnings.
Groeiende winstmarge: 0A4W became profitable in the past.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 0A4W has become profitable over the past 5 years, growing earnings by 24.5% per year.
Versnelling van de groei: 0A4W has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Winst versus industrie: 0A4W has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: 0A4W's Return on Equity (5.9%) is considered low.